Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 证券代码：603811 证券简称：诚意药业 公告编号：2025-043 浙江诚意药业股份有限公司 关于公司高级管理人员退休离任的 公 告 重要内容提示： 根据《中华人民共和国公司法》和《公司章程》等相关规定，任秉钧先生的辞职报告自送达公司董事会 之日起生效，任秉钧先生离任后将继续在公司担任其他职务。截至本公告披露日，任秉钧先生持有公司 股票5,762,455股。上述事项对公司正常的生产经营不会产生影响。 公司对任秉钧先生在担任公司副总经理期间做出的贡献和努力表示衷心的感谢！ 特此公告。 浙江诚意药业股份有限公司董事会 浙江诚意药业股份有限公司（简称"公司"）董事会收到公司副总经理任秉钧先生的书面辞职报告。任秉 钧先生因达到法定退休年龄，辞去公司副总经理职务。根据相关规定，上述辞职报告自送达董事会时生 效。 一、董事/高级管理人员离任情况 (一)提前离任的基本情况 ■ (二)离任对公司的影响 2025年8月18日 ...

证券日报网讯8月18日晚间，诚意药业（603811）发布公告称，公司董事会收到公司副总经理任秉钧先 生的书面辞职报告。任秉钧先生因达到法定退休年龄，辞去公司副总经理职务。 ...

Group 1 - Company Chengyi Pharmaceutical announced on August 18 that Mr. Ren Bingjun has resigned from the position of Deputy General Manager due to reaching the statutory retirement age [2] - The resignation report becomes effective upon delivery to the board of directors, in accordance with relevant regulations [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603811 证券简称：诚意药业 公告编号：2025-043 浙江诚意药业股份有限公司 浙江诚意药业股份有限公司（简称"公司"）董事会收到公司副总经理任秉 钧先生的书面辞职报告。任秉钧先生因达到法定退休年龄，辞去公司副总经理职 务。根据相关规定，上述辞职报告自送达董事会时生效。 关于公司高级管理人员退休离任的公告 根据《中华人民共和国公司法》和《公司章程》等相关规定，任秉钧先生的 辞职报告自送达公司董事会之日起生效，任秉钧先生离任后将继续在公司担任其 他职务。截至本公告披露日，任秉钧先生持有公司股票 5,762,455 股。上述事项 对公司正常的生产经营不会产生影响。 公司对任秉钧先生在担任公司副总经理期间做出的贡献和努力表示衷心的 感谢！ 特此公告。 浙江诚意药业股份有限公司董事会 2025 年 8 月 18 日 一、董事/高级管理人员离任情况 (一) 提前离任的基本情况 | 姓名 | 离任职务 | 离任时间 | 原定任期 到期日 | 离任原因 | 是 ...

诚意药业8月18日公告，公司董事会收到副总经理任秉钧的书面辞职报告，任秉钧因达到法定退休年 龄，辞去公司副总经理职务。根据相关规定，上述辞职报告自送达董事会时生效。任秉钧离任后将继续 在公司担任高级技术顾问（退休返聘）。 ...

金融界消息 截至2025年8月14日收盘，诚意药业（603811）报收于15.18元，下跌1.81%，换手率 9.07%，成交量29.67万手，成交金额4.58亿元。 资金流向方面，今日主力资金净流出3363.08万元，占比成交额7.34%。其中，超大单净流出2756.35万 元、占成交额6.02%，大单净流出606.73万元、占成交额1.33%，中单净流出流入2054.31万元、占成交 额4.49%，小单净流入1308.77万元、占成交额2.86%。 诚意药业最新一期业绩显示，截至2025一季报，公司营业总收入1.86亿元、同比增长21.26%，归属净利 润4579.32万元，同比增长40.10%，扣非净利润4532.86万元，同比增长46.74%，流动比率1.565、速动比 率1.042、资产负债率22.38%。 天眼查商业履历信息显示，浙江诚意药业股份有限公司，成立于2001年，位于温州市，是一家以从事医 药制造业为主的企业。企业注册资本32730.432万人民币，实缴资本32730.432万人民币。公司法定代表 人为赵春建。 通过天眼查大数据分析，浙江诚意药业股份有限公司共对外投资了8家企业，参与招投 ...

Group 1 - The stock price of Chengyi Pharmaceutical is reported at 15.65 yuan as of August 12, 2025, reflecting a decrease of 0.33 yuan from the previous trading day [1] - The opening price for the day was 16.16 yuan, with a highest point of 16.45 yuan and a lowest point of 15.26 yuan, resulting in an intraday volatility of 7.45% [1] - The trading volume reached 548,445 hands, with a total transaction amount of 870 million yuan [1] Group 2 - Chengyi Pharmaceutical primarily engages in chemical pharmaceutical business, with products covering various therapeutic areas including anti-infection drugs, anti-tumor drugs, and cardiovascular drugs [1] - The company is headquartered in Zhejiang Province and holds a certain market position in the pharmaceutical manufacturing sector [1] Group 3 - On August 12, the net outflow of main funds was 39.1563 million yuan, with a cumulative net outflow of 90.5487 million yuan over the past five trading days [1] - The stock experienced rapid fluctuations during the trading session, with a quick 2% drop at 9:37 AM followed by a 2% rebound at 9:50 AM, indicating active market trading [1]

Group 1 - The first extraordinary general meeting of shareholders for 2025 was held on August 11, 2025, at the company's research and development building in Wenzhou, Zhejiang Province [2] - The meeting was convened by the board of directors and was conducted through a combination of on-site and online voting, presided over by the chairman, Mr. Yan Yiyi [2][3] - All nine current directors attended the meeting, along with the board secretary and some senior executives [3] Group 2 - Three proposals were reviewed and approved during the meeting, including the draft of the 2025 employee stock ownership plan and its management measures [4][5] - The voting results indicated that all proposals received more than half of the valid voting rights, and the meeting ensured separate counting for minority investors [5] - Related shareholders recused themselves from voting on the proposals to maintain compliance with regulations [5] Group 3 - The meeting was witnessed by lawyers from Shanghai Jintiancheng Law Firm, who confirmed that the procedures and voting processes complied with relevant laws and regulations [5]

（文章来源：证券日报） 证券日报网讯 8月11日晚间，诚意药业发布公告称，公司2025年第一次临时股东会于2025年8月11日召 开，审议通过了《关于提请公司股东会授权董事会办理公司2025年员工持股计划相关事宜的议案》等。 ...